{"filing":{"accession_number":"0001193125-26-234848","cik":"0001750284","ticker":"OLMA","company_name":"Olema Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-05-21","report_date":null,"primary_document":"olma-20260521.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1750284/000119312526234848/olma-20260521.htm"},"events":[{"id":9433,"run_id":8272,"accession_number":"0001193125-26-234848","anchor_item_number":"8.01","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.74,"summary":"Olema Pharmaceuticals announced preliminary Phase 1 clinical data for OP-3136, a KAT6 inhibitor, demonstrating favorable safety, tolerability, and early efficacy signals including tumor shrinkage in 13 of 19 patients and 3 partial responses with no dose-limiting toxicities. This clinical progress is material to investors' assessment of the company's pipeline and development prospects.","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-05-21","form":"8-K","submitted_at":null,"items":[{"id":1074,"accession_number":"0001193125-26-234848","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces preliminary clinical data from a Phase 1 study of OP-3136, a KAT6 inhibitor. While this is clinical progress for a biopharmaceutical company, it does not fit neatly into the standard taxonomy categories. It is not an earnings release (no financial results), not an exec change, not M\u0026A, and not a restatement or going-concern issue. Clinical trial data announcements are material to investors in biotech companies as they affect pipeline value and investor sentiment, but lack a dedicated event type; therefore \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:12.784930+00:00","company_name":"","ticker":null,"filing_date":""},{"id":1075,"accession_number":"0001193125-26-234848","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces preliminary Phase 1 clinical data for OP-3136, a drug candidate in development, showing favorable safety, tolerability, and early efficacy signals (tumor shrinkage in 13/19 patients, 3 partial responses, no dose-limiting toxicities). While this is material clinical progress for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The announcement of positive Phase 1 data would affect a reasonable investor's assessment of the company's pipeline and prospects, warranting classification as a material event outside the standard taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:12.784930+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":1074,"accession_number":"0001193125-26-234848","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces preliminary clinical data from a Phase 1 study of OP-3136, a KAT6 inhibitor. While this is clinical progress for a biopharmaceutical company, it does not fit neatly into the standard taxonomy categories. It is not an earnings release (no financial results), not an exec change, not M\u0026A, and not a restatement or going-concern issue. Clinical trial data announcements are material to investors in biotech companies as they affect pipeline value and investor sentiment, but lack a dedicated event type; therefore \"other_material\" is most appropriate.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:12.784930+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-05-21"},{"id":1075,"accession_number":"0001193125-26-234848","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces preliminary Phase 1 clinical data for OP-3136, a drug candidate in development, showing favorable safety, tolerability, and early efficacy signals (tumor shrinkage in 13/19 patients, 3 partial responses, no dose-limiting toxicities). While this is material clinical progress for a biopharmaceutical company, it does not fit neatly into the more specific event categories (not an earnings release, M\u0026A activity, impairment, or litigation). The announcement of positive Phase 1 data would affect a reasonable investor's assessment of the company's pipeline and prospects, warranting classification as a material event outside the standard taxonomy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-22T02:56:12.784930+00:00","company_name":"Olema Pharmaceuticals, Inc.","ticker":"OLMA","filing_date":"2026-05-21"}]}